• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Polypill effective for blood pressure and cholesterol control in vulnerable population

byShan SuandRavi Shah, MD MBA
October 22, 2019
in Cardiology, Chronic Disease, Nephrology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized, controlled trial, patients without cardiovascular disease randomized to receive a polypill containing atorvastatin, amlodipine, losartan, and hydrochlorothiazide experienced greater reductions in systolic blood pressure and low-density lipoprotein (LDL) cholesterol over 12 months compared to patients who received usual-care.

2. Polypill patients reported increased rates of myalgia, hypotension, and lightheadedness.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Disadvantaged patients, including those with low socioeconomic status and minority populations, experience high rates of cardiovascular disease. Polypill-based therapy has not been well-studied in these underserved populations. This trial evaluated two primary endpoints: change in systolic blood pressure and change in LDL cholesterol. Compared to patients treated with usual care, patients on polypill therapy experienced greater decreases in both systolic blood pressure and in LDL cholesterol over 12 months of follow-up. Secondary endpoints, including change in diastolic blood pressure and total cholesterol, were also found to have greater decreases in polypill patients compared to usual-care patients. Compared to the usual-care group, the polypill group experienced higher rates of myalgia, hypotension, and lightheadedness.

This randomized, controlled trial provides evidence that polypill therapy may improve cardiovascular outcomes in underserved patients. Limitations include the study’s open-label design and selection of participants from one community health center.

Click to read the study in NEJM

Relevant Reading: Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

RELATED REPORTS

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

In-Depth [randomized controlled trial]: This open-label, randomized, controlled trial enrolled 303 participants (96% black; ¾ of participants with annual household income <$15,000) near Mobile, Alabama between December 2015 and July 2017. Eligible patients were 45-75 years of age, had no cardiovascular disease, and took ≤2 antihypertensive medications. Patients who did not complete a clinical questionnaire or clinical examination were excluded. Patients who were randomized to the polypill group (n=148) received 90-day refillable supplies of a polypill consisting of atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. Those randomized to the usual-care group (n=155) received routine care at the study’s health center in addition to continued care from their primary care physicians. Patients were followed-up at 2 months and 12 months for clinical and laboratory evaluations, with 275 participants (91%) completing the study. Adherence was measured using pill counts. Overall baseline blood pressure was 140/83 mm Hg, and overall baseline LDL cholesterol was 113 mg/dL. The polypill group experienced a decrease of 9 mm Hg in mean systolic blood pressure, compared to 2 mm Hg in the usual-care group (difference, -7 mm Hg; 95% confidence interval [CI], -12 to -2; P=0.003). Polypill patients experienced a decrease of 15 mg/dL in mean LDL cholesterol, compared to 4 mg/dL in the usual-care group (difference, -11 mg/dL; 95% CI, -18 to -5; P<0.001). Secondary outcomes included changes in diastolic blood pressure and changes in total cholesterol. Polypill patients experienced a -3 mm Hg greater decrease in diastolic blood pressure (95% CI, -5 to -1) and a -11 mg/dL greater decrease in total cholesterol (95% CI, -19 to -3) compared to usual-care patients. Median polypill adherence was found to be 86%. All five reported serious adverse events were found to be unrelated to the trial. The polypill group experienced a 1% rate of myalgias and a 1% rate of hypotension or lightheadedness.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: amlodipineAtorvastatinhydrochlorothiazidehyperlipidemiahypertensionlosartanpolypill
Previous Post

Wide variability in rate of antibiotic exposure among infants in NICU

Next Post

Life-gained-based selection for cancer screening may result in superior health outcomes compared to risk-based selection

RelatedReports

Renal stones in women linked with increased risk of coronary heart disease
Nephrology

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

March 22, 2023
UTI associated with increased risk of preeclampsia
Cardiology

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

March 6, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

March 6, 2023
Provision of medically-tailored meals linked with lower admissions and medical spending
Cardiology

Dietary insoluble fiber intake may be associated with lower risk of hypertension

February 22, 2023
Next Post
Smoking during pregnancy associated with aerobic fitness of children

Life-gained-based selection for cancer screening may result in superior health outcomes compared to risk-based selection

Sleep duration inversely related to childhood type 2 diabetes risk makers

Quick Take: Weight change across adulthood in relation to all cause and cause specific mortality

#VisualAbstract: Waste in the US Health Care System

#VisualAbstract: Waste in the US Health Care System

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options